Immunotherapy represents a new hope for patients with advanced urothelial carcinoma
(UC). However, to date, only one of two randomized studies showed a clear survival …

Purpose The application of platinum-based chemotherapeutic agents is the traditional
treatment paradigm for advanced and metastatic urothelial carcinoma, which has changed …

Introduction Urothelial carcinoma (UC) is an aggressive malignancy and has a poor
prognosis in the metastatic state. Treatment of UC remains a challenge, and as a first-line …

Most patients with advanced or metastatic urothelial carcinoma do not benefit significantly
from Immune checkpoint inhibitors (ICIs) use. A systematic review and meta-analysis of …

Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in
metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials …

Survival outcomes in advanced urothelial cancer (UC) are dismal. Over the past years,
immunotherapy remains an evolving treatment modality for these patients. This meta …

Opinion statement Immune checkpoint inhibitors have importantly improved the outcome of
patients with urothelial carcinoma. Different immune checkpoint inhibitors are currently …

Background Pembrolizumab and atezolizumab have recently been approved for the first-line
treatment of patients with advanced urothelial carcinoma (aUC) who are not eligible for …

Context Five checkpoint inhibitors have been approved as 1st line (cisplatin-ineligible) or
2nd line therapies for patients with metastatic urothelial carcinoma of the bladder. As only …

Urothelial carcinoma (UC) is the second most common malignancy of the genitourinary
system and the sixth most common cancer in the United States. The overall incidence of UC …